2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 ACC/AHA/HFSA guideline for the management of heart failure
ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review
P Chandrashekar, L Alhuneafat… - Circulation: Genomic …, 2021 - Am Heart Assoc
Background: The p. Val142Ile variant, predominantly found among people of African
descent, is the most common cause of variant transthyretin amyloidosis and carriers …
descent, is the most common cause of variant transthyretin amyloidosis and carriers …
2022 ACC/AHA/HFSA guideline for the management of heart failure: executive summary
ABSTRACT Background The 2022 American College of Cardiology/American Heart
Association/Heart Failure Society of America (AHA/ACC/HFSA) Guideline for the …
Association/Heart Failure Society of America (AHA/ACC/HFSA) Guideline for the …
Immunoelectron microscopy and mass spectrometry for classification of amyloid deposits
N Abildgaard, AM Rojek, HEH Møller, NB Palstrøm… - Amyloid, 2020 - Taylor & Francis
Amyloidosis is a shared name for several rare, complex and serious diseases caused by
extra-cellular deposits of different misfolded proteins. Accurate characterization of the …
extra-cellular deposits of different misfolded proteins. Accurate characterization of the …
Real-life evaluation of an algorithm for the diagnosis of cardiac amyloidosis
M Bézard, M Kharoubi, A Galat, F Le Bras… - Mayo Clinic …, 2023 - Elsevier
Objective To evaluate the real-life use of a modified Gillmore algorithm with a" one-stop-
shop” approach, bone scintigraphy (BS), a monoclonal gammopathy test (GT), a salivary …
shop” approach, bone scintigraphy (BS), a monoclonal gammopathy test (GT), a salivary …
Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare …
L Obici, R Callaghan, J Ablett, C Bibiloni, T Bueser… - BMJ open, 2023 - bmjopen.bmj.com
Background Hereditary transthyretin-mediated amyloidosis is a rare, progressive and
potentially life-limiting multisystem disease, affecting every aspect of a patient's life …
potentially life-limiting multisystem disease, affecting every aspect of a patient's life …
Counseling family members and monitoring for evidence of disease in asymptomatic carriers of amyloid transthyretin cardiac amyloidosis
N Barker, DP Judge - The American Journal of Cardiology, 2022 - Elsevier
Transthyretin (TTR), a plasma transport protein produced in the liver, is prone to misfolding,
leading to the deposition of amyloid fibrils and progressive dysfunction of cardiac and …
leading to the deposition of amyloid fibrils and progressive dysfunction of cardiac and …
Current and future circulating biomarkers for cardiac amyloidosis
Cardiac amyloidosis (CA) comprises a heterogeneous group of medical conditions affecting
the myocardium. It presents with proteinaceous infiltration with variable degrees of severity …
the myocardium. It presents with proteinaceous infiltration with variable degrees of severity …